Exercise on tirzepatide is generally part of the same longer-term plan as the medication, not a separate requirement or a special workout. In the main obesity trial, everyone received activity and food counseling. The study did not compare tirzepatide alone with tirzepatide plus exercise, so it cannot tell us which routine is best. It can tell us that movement belonged in the treatment setting from day one.
The more careful answer matters if nausea, low food intake, diabetes medicines, or a loss of strength is changing what activity feels like. Those are questions for the prescribing provider, not reasons to copy a trial target.
What exercise on tirzepatide meant in SURMOUNT-1
SURMOUNT-1 was a 72-week trial of 2,539 adults with obesity or overweight and a weight-related condition, but without diabetes. Participants received tirzepatide or placebo, and every group received the same lifestyle support (Jastreboff et al., New England Journal of Medicine 2022).
The protocol called for counseling around at least 150 minutes of activity per week and a food plan about 500 calories per day below estimated needs. The current Zepbound label describes that as a recommended minimum and says participants also received behavior-change counseling. It was a shared trial target, not proof that every person completed exactly 150 minutes.
The trial did not assign a particular strength routine or test whether morning workouts beat evening ones. Its weight results therefore describe tirzepatide inside a supported lifestyle plan, not the effect of exercise by itself.
The lean-mass number needs careful language
A 160-person SURMOUNT-1 substudy used DXA, a low-dose scan that separates fat, bone mineral, and lean soft tissue. After 72 weeks, the tirzepatide group had average reductions of 21.3% in body weight, 33.9% in fat mass, and 10.9% in lean mass. Of the weight lost, 74% was fat mass and 26% was lean mass (Look et al., Diabetes, Obesity and Metabolism 2025).
That does not mean 26% of the loss was muscle. DXA lean soft tissue excludes bone mineral and includes muscle, but also water, organs, skin, and connective tissue. The scan did not measure strength or prove that tirzepatide directly broke down muscle.
This is why the scale and even a body-composition scan tell only part of the story. The broader GLP-1 muscle-loss evidence belongs on its own page; the tirzepatide-specific point is narrower. Substantial weight reduction in this substudy included some lean soft tissue, while fat accounted for roughly three-quarters of the loss.
Low blood sugar and hydration during workouts
As of September 18, 2026, the day this article was written, the current Zepbound label was updated August 28, 2026. It does not list exercise as a drug interaction. It says tirzepatide can lower blood glucose and reports low glucose below 54 mg/dL in 4.2% of trial participants with type 2 diabetes taking Zepbound, versus 1.3% taking placebo.
The risk was higher when Zepbound was combined with a sulfonylurea, a diabetes medicine that pushes the pancreas to release insulin: 10.3% with that combination versus 2.1% without it. The label also identifies added risk with insulin and notes that low blood sugar has occurred in adults without type 2 diabetes. The practical issue around exertion is therefore a person's full medication and health picture, not a forbidden pairing between tirzepatide and movement.
Hydration is a separate concern. The same label describes postmarketing kidney-injury reports, most often after nausea, vomiting, or diarrhea led to dehydration. Sweating during activity can add fluid loss, but the label does not claim that exercise itself causes kidney injury. Coffee raises the same hydration and stomach-emptying questions; tirzepatide and caffeine covers them. A provider can distinguish an ordinary change in workout tolerance from a medication effect, low glucose, or volume depletion, meaning too little fluid in circulation.
What the exercise studies can and cannot tell us
The strongest randomized exercise evidence in this drug family used liraglutide, not tirzepatide. In a 2021 trial, 195 adults who had completed an eight-week low-calorie diet entered one of four groups for a year: exercise, liraglutide, both, or placebo. The combined group maintained more weight loss than exercise alone (−5.4 kg) but not significantly more than liraglutide alone (−2.7 kg; 95% CI −6.3 to 0.8; P=0.13); it also had a larger drop in body-fat percentage and improved cardiorespiratory fitness (Lundgren et al., New England Journal of Medicine 2021). That supports the idea that planned exercise and a GLP-1 medicine can work alongside each other. It does not establish a tirzepatide workout plan.
As of September 18, 2026, the day this article was written, newer evidence still leaves that plan unsettled. A July 3 review in the International Journal of Obesity found no significant overall difference in objectively measured activity across three comparable randomized GLP-1 trials; structured-exercise participation was similar between groups. All included studies used older medicines such as liraglutide or exenatide, not tirzepatide.
An August 10 tirzepatide case series followed 93 men who also received testosterone, resistance-focused coaching, nutrition support, and weekly behavioral support. Grip strength and estimated skeletal muscle rose, even as total lean body mass fell. Because there was no control group and several treatments changed together, the study cannot show which part caused the result.
Why activity comes up during the intake
A provider may ask about current activity to understand the starting point, not to grade a person's fitness. Baseline strength, balance, joint limits, heart or kidney conditions, diabetes medicines, dizziness, nausea, vomiting, and recent changes in food intake can all change how exertion is interpreted. The useful plan is the one that fits that medical picture.
Food has its own role, especially when appetite is small; the tirzepatide meal-plan guide covers that question without turning exercise into a nutrition program.
Through Promise, tirzepatide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor. A licensed provider reviews every request, and not everyone qualifies.
What the evidence really supports
The plain answer is that exercise belonged in the tirzepatide trials, and body-composition data make strength and function worth discussing. But no study has established one best exercise program for people taking tirzepatide. The evidence is strongest for a provider matching activity to current ability, other medicines, symptoms, and the pace of weight change rather than borrowing a fixed routine from the internet.
